Chronic hepatitis D coinfection affects an estimated 12 million people globally, with higher prevalence in low-income and middle-income countries, especially the African and Western Pacific regions.

As outlined in Table 1, the new PCO recommends that when HBV screening is pursued, both HB surface antigen (HBsAg) and HB core antibody (anti-HBc) be tested. 10 It also recommends against screening ...

In the seventeen month time period of this retrospective study, there were 11,719 HBsAg tests ordered for 9,930 patients (with some patients being tested two or more separate times during the time ...

Hepatitis B is a viral infection that impacts the liver. To test for hepatitis B, a doctor can perform a blood test that detects hepatitis B surface antigens. A positive result indicates a hepatitis B ...

- New point-of-care rapid test identifies and helps make effective care more accessible for millions of people living with hepatitis B, in support of World Health Organization (WHO) hepatitis targets ...

A decision model was developed to compare the clinical outcomes, costs, and cost effectiveness of three HBV screening strategies for patients with lymphoma before R-CHOP (rituximab plus ...

Hepatitis B core antibody (HBcAb) is the first antibody to appear following acute hepatitis B infection and will persist in high levels following resolution of infection and in chronically infected ...

Chronic hepatitis D virus (HDV) coinfection in people with chronic hepatitis B is associated with rapid progression to liver cirrhosis and high mortality. In 2020, the estimated global HDV burden ...